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Abstract: Heme is a ubiquitous and essential iron containing metallo-organic cofactor required for
virtually all aerobic life. Heme synthesis is initiated and completed in mitochondria, followed by
certain covalent modifications and/or its delivery to apo-hemoproteins residing throughout the
cell. While the biochemical aspects of heme biosynthetic reactions are well understood, the
trafficking of newly synthesized heme—a highly reactive and inherently toxic compound—and its
subsequent delivery to target proteins remain far from clear. In this review, we summarize current
knowledge about heme biosynthesis and trafficking within and outside of the mitochondria.
Keywords: mitochondria; heme; porphyrin; heme biosynthesis; membrane transporters;
hemoproteins

1. Introduction
Heme b, or iron protoporphyrin IX (Fe-PPIX), is an essential but potentially cytotoxic protein
prosthetic group and signaling molecule. The paramount importance of this metallocofactor is
highlighted by the plethora of hemoproteins present in virtually every subcellular compartment that
fill vital roles within the eukaryotic cell. As a cofactor, heme is essential for mediating gas synthesis,
storage and transport; electron transfer; and chemical catalysis [1–6]. As a signaling molecule, heme
binding to a number of cellular factors including transcription factors, kinases, ion channels and
micro RNA processing proteins [5,7–9] or its catabolism to the signaling molecule, carbon monoxide
(CO), collectively regulate diverse physiological processes that include oxygen sensing, iron
homeostasis, the oxidative stress response, mitochondrial respiration and biogenesis, mitophagy,
apoptosis, circadian rhythms, cell cycle progression and proliferation [1,7,10–19]. Another vital role
for heme b is to act as a precursor for the synthesis of other heme types important for eukaryotic
physiology, including hemes c, o and a (Figure 1).
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Figure 1. Chemical structures of the various heme types in eukaryotes. Starting with the heme b
precursor (protoheme), heme c is made through covalent attachment to the sulfhydryl moieties of
either cytochrome c or complex III subunit cytochrome c1; this process is assisted by the cytochrome c
lyases. Heme a is synthesized from heme b through the sequential action of heme o synthase and
heme a synthase enzymes, going through the intermediate, heme o.

All of the aforementioned heme-dependent processes require that heme is dynamically
mobilized from its site of synthesis on the matrix side of the mitochondrial inner membrane to
heme-dependent proteins throughout the cell [2,3]. However, since heme is a hydrophobic and
cytotoxic species [20,21], cells are challenged to mitigate heme toxicity by appropriately regulating
cellular heme concentration and bioavailability. The concentration of heme is dictated by the relative
rates of its synthesis and degradation [2,3]. Despite the fact that all of the proteins involved in the
synthesis and degradation of heme have been structurally characterized to atomic resolution and
detailed kinetic studies have revealed their mechanisms of action [2,3], our understanding of how
the relative rates of heme synthesis are regulated remains far from clear. Furthermore, the
bioavailability of heme is governed by its transport and trafficking; yet, the molecules and
mechanisms that mediate these processes are poorly understood.
Herein, we review the “ins and outs” of heme synthesis, trafficking and utilization, both inside
and outside the mitochondria. In particular, we will first discuss the biosynthesis of heme and how it
may be regulated to affect heme bioavailability. Next, we will discuss the mechanisms underlying
how protoheme IX, or heme b, is trafficked and converted to alternative heme types, including
hemes c, o and a and how it can exit the mitochondria and be mobilized for use in hemoproteins
throughout the cell. Finally, we discuss the latest approaches and technologies that can be utilized to
characterize heme transport and trafficking mechanisms. Where appropriate, we will highlight open
questions regarding heme homeostatic mechanisms. The mobilization of heme for trafficking and
signaling, of which little is understood, represents a challenging frontier in heme cell biology. A
better understanding of heme transport is essential for treating numerous diseases associated with
defects in heme homeostasis, including certain cancers, cardiovascular diseases and
neurodegenerative disorders [19,22–25].
2. Heme Biosynthesis
Cells mitigate the toxicity of heme in part by coordinating heme synthesis (see Table 1) with
heme utilization [1]. Animals, fungi and α-proteobacteria make heme via the C4 (Shemin) pathway,
whereas plants, archaea and other bacteria utilize the C5 (glutamate) pathway [26]. Here, we focus
on the former, which requires eight enzymes to construct heme from glycine, succinyl-CoA,
molecular oxygen (O2) and iron (Fe) [12,27,28]. The first and last three enzymes of the heme
synthesis pathway in animal and fungi are localized to the mitochondria and the remaining four
enzymes reside in the cytosol. Heme synthesis can therefore be controlled at multiple levels,
including substrate availability, partitioning of heme synthetic intermediates between the
mitochondria and cytosol and direct regulation of the heme biosynthetic enzymes [1,29,30] (Figure
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2). In this section we examine each of the enzymes involved in heme synthesis, focusing on their
regulation and thus their ability to control heme availability.
Table 1. Conservation of heme homeostatic factors between yeast, worm and man.

Heme
Homeostatic
Process

Enzyme

Saccharomyces
cerevisiae

Caenorhabditis
elegans

Homo sapiens

5-aminolevulinic acid
synthase

Hem1

✖

ALAS1/ALAS2

Porphobilinogen
synthase

Hem2

✖

PBGS

Hydroxymethylbilane
synthase

Hem3

✖

HMBS

Uroporphyrinogen
synthase

Hem4

✖

UROS

Uroporphyrinogen
decarboxylase

Hem12

✖

UROD

Coproporphyrinogen
oxidase

Hem13

✖

CPOX

Protoporphyrinogen
oxidase

Hem14

✖

PPOX

Ferrochelatase

Hem15

fecl-1

FECH

Heme
Degradation

Heme oxygenase

Hmx1

?

Hmox1/Hmox2

Heme

FLVCR2

✖

✔

✔

Import

HRG4

✖

✔

✖

FLVCR1

✖

✖

✔

Heme

MRP5

✖

mrp-5

ABCC5

Export

Pug1

✔

✖

✖

HRG3

✖

✔

✖

PGRMC1/2

Dap1

vem-1

PGRMC1/2

GAPDH

Tdh1/2/3

gpd1/2/3/4

GAPDH

HRG1

✖

✔

✔

Heme
Synthesis

Heme
Trafficking
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Figure 2. Structures and enzymes involved in heme synthesis shown where they are localized.
Glycine is transported into the intermembrane space of the mitochondria (IMS) through an unknown
mechanism and is transported across the inner mitochondrial membrane (IMM) by SLC25A38.
Succinyl-CoA is synthesized within the matrix. Glycine and Succinyl-CoA are condensed into
5-aminolevulunic acid (5-ALA) by ALA synthase (ALAS). The 5-ALA is transported from the matrix
to the cytosol by unknown mechanisms, where Porphobilinogen synthase (PBGS) condensates two
molecules of ALA into porphobilinogen (PBG). Four molecules of PBG are combined to form a linear
tetrapyrrole hydroxymethylbilane (HMB) by hydroxymethylbilane synthase (HMBS).
Uroporphyrinogen III (UPgen III) is synthesized from HMB by uroporphyrinogen synthase (UROS).
Coproporphyrinogen III (CPgenIII) is synthesized from UPG III by uroporphyrinogen decarboxylase
(UROD). CPgenIII is transported by an unknown mechanism into the IMS. Within the IMS CPgenIII
is made into protoporphyrinogen IX (PPgen IX) through catalysis by CPgen oxidase (CPOX). Next,
PPgen IX is oxidized into protoporphyrin IX (PPIX) by PPgen oxidase (PPOX). For the final step PPIX
is transported into the matrix, where ferrochelatase (FECH) catalyzes the insertion of ferrous iron
into the porphyrin ring, resulting in heme b.
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2.1. ALA Production
The first committed step of heme biosynthesis in non-plant eukaryotes occurs with the
pyridoxal 5’-phosphate (PLP)-dependent condensation of glycine and succinyl-CoA to form
aminolevulinic acid (ALA) by ALA synthase (ALAS) in the mitochondrial matrix (Figure 2). ALAS is
conserved from bacteria to metazoans [31] and is the universal precursor for all tetrapyrroles
including chlorophylls, cobalamin, siroheme and coenzyme F430 [31,32]. The supply of glycine from
the cytosol into the matrix of the mitochondria for ALA production likely occurs by passive
diffusion across the highly porous outer mitochondrial membrane (OMM) and then through the
inner mitochondrial membrane (IMM) by Solute Carrier (SLC) family 25A38 (Hem25 in yeast)
[33,34]. In yeast, one secondary glycine transporter, Ymc1 (another SLC family member), has been
determined, but it is currently not known whether this protein has a homolog in humans [35]. The
other ALAS substrate, succinyl-CoA, is synthesized in the mitochondrial matrix, primarily from
either α-ketoglutarate (α-KG) via α-KG dehydrogenase or succinate via succinyl-CoA synthetase in
a cell-specific manner [36–39].
ALAS structures obtained from α-proteobacterium [40] and yeast [41], both with a high degree
of sequence homology to the human ALAS core, indicate a tightly bound homodimer. Specifically,
each monomer consists of three domains that all participate in dimerization: a variable N-terminal
region, a highly conserved catalytic center with a PLP-lysine Schiff base in the active site and a
regulatory
C-terminal
domain.
Eukaryotic
ALAS
proteins
contain
a
cleavable
mitochondrial-targeting sequence (MTS) at the N-terminus and a well-conserved extension of the
bacterial C-terminal domain that putatively influences substrate binding [41] and ALA product
release [42]. Multiple heme regulatory motifs (HRMs) have been identified in the N-terminal domain
of eukaryotic ALAS, including in the MTS, with the notable exception of yeast [43–45]. Perhaps not
coincidentally, ALA synthesis is the rate-limiting step in mammalian heme synthesis [28] but not in
yeast [46].
Two highly conserved forms of ALAS, ALAS1 and ALAS2 are expressed in mammals [47].
ALAS1 is ubiquitously expressed, while ALAS2 is specific to erythroid cells [48]. In nonerythroid
tissue, feedback inhibition by heme negatively regulates ALAS1 transcription [49], translation
[50,51], mRNA stability [52], protein stability in the mitochondria [53] and mitochondrial import via
the MTS [54] to avoid free heme accumulation and toxicity. In contrast, ALAS2, which operates in
erythroid cells that are obligated to make upwards of ~80 mM heme or ~5 × 109 molecules of heme
per cell for hemoglobin assembly [55], is not inhibited by heme at any level. ALAS2 synthesis is
modulated transcriptionally by GATA-1 and other heme-independent factors [56,57] and
downregulated post-transcriptionally by microRNA [58] and iron regulatory proteins (IRPs) [59].
Interestingly, the inhibitory effect of IRP1 and IRP2 via interaction with an ALAS2-specific 5’-iron
regulatory element (IRE) is abrogated by iron and/or heme [60,61], suggesting that heme could
indirectly stimulate ALAS2 translation. Unlike in ALAS1, N-terminal HRMs present in ALAS2
protein do not render mitochondrial import sensitive to heme [54]. Post-translational events that
impact enzyme activity include the binding of ALAS2 and the AAA+ unfoldase, CLPX, a complex
which facilitates both PLP binding and ALAS2 degradation [62], as well as hydroxylation of the
ALAS2 C-terminal extension and the associated proteosomal degradation of the protein [63].
2.2. CPgenIII Formation
After formation of ALA by ALAS, ALA is transported out of the mitochondria back into the
cytosol by unknown mechanisms (Figure 2). Proposed ALA transporters include SLC25A38 [33]
and SLC25A39 [64], though these transporters have been implicated in glycine transport [34] and
iron-sulfur cluster biogenesis [64] and direct evidence of ALA transport via either is lacking. For
transport of ALA from the IMS to the cytosol, it is possible that ALA may simply diffuse across the
OMM given the permeability of this membrane to small molecules. Once in the cytosol, ALA is
converted in four consecutive steps into CPgen III (Figure 2). These steps include condensation of
two ALA molecules into a single monopyrrole, porphobilinogen (PBG), by the enzyme
porphobilinogen synthase (PBGS) ((previously known as ALA dehydratase (ALAD)); the
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head-to-tail synthesis of four PBG molecules to form the linear tetrapyrrole, hydroxymethylbilane
(HMB), by the enzyme hydroxymethylbilane synthase (HMBS) (previously called porphobilinogen
deaminase (PBGD)); the spiro inversion and cyclization of HMB to form uroporphyrinogen III by
uroporphyrinogen synthase (UROS); and the decarboxylation of the four pyrrole acetic acid side
chains by uroporphyrinogen decarboxylase (UROD) to yield the final product CPgen III and four
molecules of carbon dioxide [12,65]. In contrast to other eukaryotes, PBGS and HMBS (not ALAS)
reactions are rate limiting in yeast heme biosynthesis [46].
2.3. Coproporphyrinogen Oxidase (CPOX) and Protoporphyrinogen Oxidase (PPOX)
Once generated, CPgen III is then transported by a currently unknown mechanism into the
intermembrane space of the mitochondria (IMS) (Figure 2). One study posited that OMM
ATP-dependent transporter ABCB6 has a role in this process [66]. However this postulate has been
debated based on the cellular localization of ABCB6 [66,67], with biochemical studies which
demonstrated binding and transport of porphyrins and not porphyrinogens [66,68,69] and findings
from animal studies [68,69]. Thus, additional studies are necessary to further investigate the role of
ABCB6 as a CPgen III transporter in heme synthesis. Once CPgen III is in the IMS, the enzyme
coproporphyrinogen oxidase (CPOX) converts it to PPgen IX followed by conversion to
protoporphyrin IX (PPIX) by protoporphyrinogen oxidase (PPOX), a reaction that requires three
molecules of oxygen and generates three molecules of hydrogen peroxide (H2O2) [12]. A recent study
employing proximity labeling, mass spectrometry and electron microscopy showed that PPOX
localizes to the matrix-facing side of IMM [70]. These data suggest that PPgen IX rather than PPIX
traverses the IMM (Figure 2). The N-terminal moiety of CPOX is anchored in the IMM, so the direct
transfer via lipid bilayer is one possible scenario. Alternatively, the transfer could involve a
transporter. It was shown that in yeast, heme and some of its precursors may associate specifically
with the adenine nucleotide translocator (ANT) and that this binding is inhibited by the ANT
substrate ADP [71]. Additionally, Azuma et al. [71] found that disruption of the ANT genes in yeast
(AAC1, PET9 and AAC3) resulted in a reduction of heme biosynthesis via blockage of precursors
from entering the matrix. These transporters may therefore play certain role in tetrapyrroles
transport to PPOX and/or FECH. These findings also suggest that ATP:ADP ratios, mitochondrial
protonmotive force and cellular energy status may regulate heme synthesis in response to changes
in metabolic demand thus further studies are warranted to elucidate this issue. Another recently
identified protein which may function in PPgen IX transport is the protein TMEM14C. This protein
was originally identified in a large-scale gene expression analysis [64] and shown to be important for
erythropoiesis in zebrafish. Yien et al., [72] expanded these studies and their data demonstrate that
TMEM14C is important for porphyrin precursor homeostasis thus supporting TMEM14C as a PPgen
IX transporter.
2.4. Ferrochelatase
The final step of heme synthesis involves the insertion of ferrous iron into the PP IX molecule to
produce protoheme by the enzyme ferrochelatase (FECH or Hem15) on the matrix side of the inner
membrane (Figure 2). Iron appears to be delivered to FECH via the transporters mitoferrin 1 (MFN1
or SLC25A37) and mitoferrin 2 (MFN2 or SLC25A28) in mammals [73]. A number of recent
outstanding reviews focusing on iron delivery to mitochondria can be found elsewhere [74–77].
FECH functions by removing two protons from PP IX and inserting Fe2+. Mammalian FECH
functions as a homodimer where each subunit contains a [2Fe-2S] cluster [78]. While the [2Fe-2S]
cluster is necessary for enzyme activity [79,80], there is no evidence to support its role in catalysis.
Work by Shah et al., [81] indicates that it may be serving as a sensor for the redox or membrane
potential in the mitochondrial matrix. Thus, redox signals may serve to integrate energy metabolism
with control of heme synthesis.
Recent biochemical and mass spectrometry-based studies have suggested that the heme
biosynthetic machinery forms a large complex, termed the mitochondrial heme metabolon [39,82–
84]. Indeed, FECH was found to be a component of a multimeric assembly that included the first and
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seventh enzymes in the heme synthesis pathway, ALAS and PPOX, respectively. In addition,
α-ketoglutarate dehydrogenase (KDH) and succinyl-CoA synthase (SUCLA2), which synthesize the
heme precursor succinyl-CoA, and TMEM14C, a porphyrinogen transporter [39,82], were also
observed in the complex. Independent studies have also shown mitoferrin, a mitochondrial iron
importer [84], as well as two ATP binding cassette proteins, ABCB7 [85,86] and ABCB10 [84,86] are
protein partners of FECH. These results would suggest that substrate channeling and assembly of
the heme metabolon complex may be a key regulatory node for heme synthesis. Most intriguingly,
the putative heme chaperones progesterone receptor membrane component 1 (PGRMC1), which has
been previously proposed to deliver heme to cytochrome P450 enzymes [87–89] and progesterone
receptor membrane component 2 (PGRMC2), which delivers heme to nuclear heme dependent
transcription factors in adipose tissue [90] also interacts with FECH [83]. This would suggest that
certain heme acceptor proteins may interact with the heme metabolon in order to provide an outlet
valve for heme distribution to other locales. Altogether, FECH may not just be important for heme
synthesis, but also for mediating heme trafficking and distribution via its interactions with other
factors.
Once synthesized, heme is trafficked to other cellular locations, including the matrix, the IMM,
IMS and any number of extra-mitochondrial locales. However, the molecules and mechanisms that
mobilize heme from its site of synthesis are not well defined. Recent work supports the role of a
number of proteins in this distribution, including glyceraldehyde phosphate dehydrogenase
(GAPDH) [91,92], PGRMC1 [83] and PGRMC2 [90]. Further, it is unclear how the demand for heme
in different cellular locations regulates the distribution of heme from FECH.
2.5. Anemias and Porphyrias
Disorders in heme synthesis can result in pathological conditions in humans. The most common
of these are the anemias which result from a decrease in the number of circulating erythrocytes
and/or the amount of hemoglobin in erythrocytes. The most common anemia world-wide is iron
deficiency anemia in which heme production during erythroid development is limited due to a
deficiency of iron in the diet. This is particularly problematic in women of child-bearing age in
third-world countries, since frequent pregnancies deplete body iron stores. Second only to iron
deficiency are anemias of chronic disease. These anemias result from the body’s inflammatory
response to infection or disease. A deficiency in ALAS2, the first enzyme in the pathway in erythroid
precursors, results in sideroblastic anemia [93]. Sideroblastic anemia is characterized by iron
accumulation in mitochondria and diminished erythroid cell development. In the case of ALAS2
mutations, iron is available, but heme synthesis is limited.
The disorders known as the porphyrias are caused by aberrant heme synthesis and the
concomitant buildup of cytotoxic intermediates in hepatic and/or erythroid tissue. These
intermediates may produce symptoms of acute neurological dysfunction and/or cutaneous
photosensitivity [94]. Mutations have been identified in all enzymes of the heme biosynthetic
pathway except ALAS1 (see reference [93] for comprehensive review). Interestingly induction of
ALAS1 in liver resulting from elevated heme oxygenase activity [95], consumption of xenobiotics
[96] or steroids [97] and poor nutrition [98] can precipitate acute porphyric attacks. The most
recently discovered porphyria is X-linked protoporphyria, which results from gain-of-function
mutations in ALAS2 [99]. This porphyria resembles erythropoietic protoporphyria, which is caused
by decreased FECH activity. This phenotype similarity points to metal chelation by FECH as a
second regulatory step in heme synthesis and hints at some level of regulatory coordination between
the first and last steps of the pathway.
At present, there are idiopathic anemias and porphyrias for which no underlying molecular
cause has been identified. The identification of the multi-protein mitochondrial heme metabolon and
other protein partners of heme biosynthesis enzymes opens a black box that in time may shed light
on additional means of heme synthesis regulation. Clearly any mutations in these interacting
proteins that cause dysfunction in heme synthesis may contribute to porphyrias and anemais. One
example is a recently discovered CLPX mutation, which has been implicated in porphyria [62].
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Additional studies on the function and interactions among the protein components will further our
understanding of the regulation of heme synthesis and, thus, the pathophysiology of the anemias
and porphyrias.
3. From Heme b to Hemes c, o and a
All mitochondrial heme species are generated from the heme b produced by FECH (Figure 1).
Each of the different heme species is necessary for a specific function and is generated by its own
diverging pathway. While much is known regarding heme synthesis, less is known about heme
modification and distribution and most available information has been largely elucidated in yeast
studies. Since the heme b product release by FECH is rate-limiting [100], the interaction between
FECH and heme chaperone is likely what regulates and distributes heme throughout the cell [12].
This protein-mediated shuttling of heme is the probable means of distribution, as “free” heme is
inherently toxic and can catalyze the formation of harmful reactive oxygen species [12,101]. These
predictions are in line with a recent report estimating that less than one molecule of exchange-labile
heme is available in the mitochondrial matrix compartment [92].
As noted above, all other species of heme are generated from heme b, including hemes a, heme o
and heme c. These different species of heme diverge from one another due to various modifications
of the porphyrin ring. Heme c is the only heme that is covalently bonded to the protein in which it is
assembled. The two vinyl (C=C) side chains of heme c are covalently attached to the cysteine
sulfhydryl residues of the apoprotein (Figure 1). Two examples of heme c containing proteins are the
cytochromes c and c1. Heme o and heme a are formed in a two-step consecutive process by the
proteins Heme o Synthase (Cox10) and Heme a Synthase (Cox15), respectively. Heme o is modified
from heme b by the farnesylation of a vinyl group at the C2 position of the porphyrin ring [6,102] and
heme a has the C8 methyl substituent oxidized to an aldehyde group on top of this [103–106] (Figure
1). In all cases, heme b must be mobilized from FECH via currently unknown mechanisms to be
converted into these other heme types.
In eukaryotes, heme o exists only as long as it takes to convert it to heme a. In some bacteria,
however, heme o can be used as a prosthetic group in some terminal oxidases, such as cytochrome
o-containing bo3 oxidase—one of two terminal ubiquinol oxidases in Escherichia coli [107]. The bo3
oxidase is both structurally and functionally related to cytochrome c oxidase (CcO) of mitochondria
and bacteria, except that heme o cannot function as a prosthetic group in these other species [108].
Heme a is utilized in the active site of Cox1, the central core subunit of CcO, or Complex IV, of the
electron transport chain (ETC). CcO harbors two heme a molecules—heme a and heme a3—the
distinction between the two being their coordination geometries within the protein. Heme a is a 6
coordinate, low spin, cofactor and heme a3 is a 5 coordinate, high spin, cofactor, giving two identical
molecules with significantly different physical and chemical properties within CcO. This is the only
known physiological function of heme a [6,108]. In the following sections of this review, we will
summarize currently available information regarding mitochondrial hemoproteins and highlight
gaps in our knowledge related to the distribution of different heme species to these proteins.
3.1. Mitochondrial Heme b Pathways
Heme b (aka Protoheme IX) is utilized as a cofactor by several mitochondrial
proteins/complexes (Figure 3). These include mitochondrial matrix-localized flavohemoglobin Yhb1
(neuroglobin in mammals) [6,109], IMM-anchored ETC enzymes ubiquinol-cytochrome c
oxidoreductase (complex III, bc1 complex) [110] and succinate dehydrogenase (complex II)
[6,111,112]. Additionally, yeast mitochondria harbor several fungi-specific hemoproteins such as
CcO assembly factor Mss51 [113], cytochrome c peroxidase Ccp1 [114] and L-lactate cytochrome c
oxidoreductase Cyb2 [115]. Remarkably little is known about how heme b is transported to these
targets. As exemplified by studies on hemylation of complex III, formation of heme b catalytic
centers is an early post-translational event in the assembly of these molecules [6,116]. Such setting
likely assures an effective heme-dependent regulatory mechanism, thereby reducing potential
negative effects of cofactor’s exposure.
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Figure 3. Mitochondrial heme routes. Mitochondrial enzyme ferrochelatase (FECH) metallates PP IX,
yielding protoheme that is routed to several suborganellar locales, wherein heme b is sequentially
modified and/or inserted into the indicated hemoproteins. SDH, succinate dehydrogenase; CcO,
cytochrome c oxidase; OMM, outer mitochondrial membrane; IMS, intermembrane space; IMM,
inner mitochondrial membrane.

3.2. Heme c Pathway
Unlike the other heme types, heme c needs to be covalently attached to its client proteins –
cytochrome c (Cyc1) and complex III subunit cytochrome c1 (Cyt1). In each case, hemylation of these
proteins involves the formation of two stereospecific thioether bonds between two cysteine residues
of protein’s conserved Cys-X-X-Cys-His motif and two vinyl groups of the protoheme. The histidine
residue is an axial ligand to heme iron. The covalent attachment of heme to c-type apo-cytochromes
is critical for their stability and subsequent maturation and has been extensively studied [6,117,118].
In yeast, hemylation of apo-Cyc1 and apo-Cyt1 is mediated by either of the two IMS-localized
cytochrome c heme lyases—CCHL (Cyc3) and CC1HL (Cyt2) [117,119]. In mammals, a single
enzyme, holocytochrome c synthase (HCCS), is responsible for the covalent heme attachment. All
mitochondrial CCHL proteins appear to use the following modus operandi: IMM-bound lyase binds
reduced Fe-PPIX, which is followed by binding of apocytochrome c or c1 and subsequent formation
of covalent thioether bonds and release of hemylated cytochrome [120]. Although heme binding to
CCHL proteins is well characterized [120], how reduced heme is transported to CCHL proteins
across IMM remains to be determined.
In vitro analyses indicate that c-heme lyases can directly catalyze the formation of a thioether
bond within the CCHL–ferrous heme-apocytochrome c/c1 complex, wherein apocytochrome
provides the second histidinyl ligand to this complex with the first axial ligand being supplied by
invariant histidine residue of CCHL. However, a scenario whereby CCHL proteins merely serve as
stereospecificity-assuring chaperones allowing for spontaneous thioether bond formation is also
possible. Likewise, it remains to be determined whether any additional proteins may be facilitating
this process in vivo. For instance, studies in yeast identified the IMS-residing flavoprotein Cyc2 that
might function as a heme reductase or redox modulator of heme lyase reactions [121,122]. Because
Cyc2 is not absolutely required for CCHL function and is not conserved outside fungi, its
physiological significance remains somewhat unclear. Nevertheless, these findings suggest that
additional factors may be involved in the maturation of c-type cytochromes in vivo.
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Once heme is covalently ligated, the resulting holocytochrome c/c1 is released from heme lyase.
The release is facilitated by several factors including conformational distortion of the heme molecule
upon its covalent biding to cytochrome c/c1 [120,123] and holocytochrome’s axial ligand-mediated
dwindling of heme-CCHL adducts [118,120]. Interestingly, the heme lyase’s residues that have been
implicated in heme coordination also appear to contribute to its release [120]. Upon its hemylation
the stabilized cytochrome c is further folded into its functional conformation and cytochrome c1 is
conveyed for further incorporation into maturing bc1 complex. It will be interesting to test whether
hemylation of cytochromes b and Cyt1 are coordinated molecular events.
3.3. Heme a Pathway
Heme a is a modified Fe-PPIX uniquely used by CcO, a key heme-copper enzyme of the ETC
[6,124]. Two heme a molecules with different coordination geometries—designated a and a3—reside
in the Cox1 core subunit of CcO and are essential for catalysis and the stability/folding of Cox1
[6,125]. Hemylation of Cox1 is a sequential post-translational process [6,126,127]. Heme a synthesis
requires the shuttling of the compound’s precursors—hemes b and o—between heme a biosynthetic
factors, and the subsequent shuttling of mature heme a to maturing CcO. This process is mediated
by a number of different assembly factors [128–131], but much remains to be elucidated in terms of
the molecular mechanisms at work.
3.3.1. Heme o Synthase
As discussed earlier, heme o synthase, Cox10, is the protein responsible for converting one of
the vinyl carbons of the heme b’s macrocycle into a hydrophobic hydroxyfarnesyl tail, yielding heme
o, the precursor for heme a (Figure 1) [102]. This evolutionarily conserved 46 kDa-enzyme is intrinsic
to the IMM and it is predicted to contain 8 to 9 transmembrane helices that form a catalytic site on
the matrix face of the inner membrane. Cox10 assembles in presumably homo-oligomeric complexes
of approximately 300 kDa [132,133]. Some structure-function insights into Cox10 can be potentially
gleaned from the recently solved structure of UbiA, a distantly related bacterial prenyl transferase
[134], but no information exists on how heme b is shuttled to Cox10’s active site. Cox10
multimerization seems to be dependent upon the presence of newly synthesized Cox1 and its early
assembly intermediates [131–133]. The oligomerization, but not steady state levels, of Cox10 is
dependent upon the presence of the yeast-specific Cox10 effector protein Coa2 [132,133]. However,
the gain-of-function mutation of Cox10, N196K that lies close to matrix side of TMD2 suppresses the
Coa2 deletion phenotype [132]. Identification of the N196K substitution led to the conclusion that
Cox10 activation may be linked to a multimeric structure. Because Cox10 is present at approximately
8-fold lower abundance than the heme a synthase enzyme discussed below, the synthesis of heme o
is likely the rate-limiting step of heme a production [135].
3.3.2. Heme a Synthase
Heme a synthase, Cox15, catalyzes the conversion of heme o to heme a. Cox15-mediated
conversion of one ring methyl carbon to a formyl group increases the mid-point potential of heme a
approximately +180 mV, thereby permitting more efficient catalysis by CcO [136,137]. This enzyme
is highly conserved from bacteria to humans, allowing for much insight in its function to be
garnered from model organisms such as Saccharomyces cerervisiae. Cox15 is proposed to have eight
transmembrane domains (TMDs) and is anchored in the IMM. Of these eight TMDs, models of
Cox15 predict the protein to contain two domains, each comprised of a 4 helix bundle connected by a
short (approximately 20 amino acids) unstructured linker region. A very recently solved crystal
structure of Bacillus subtilis heme a synthase homolog confirms these predictions [138]. Removal of
the linker region impairs Cox15 function, suggesting its importance in enzyme activity [139]. The
sequence similarity between the first domain and the second suggest the possibility of a gene
duplication occurring early in its evolutionary history. Cox15 has been found to form higher-order
homo-oligomeric protein complexes, on the range of the ~350–450 kDa in size, however the
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importance of the formation of these complexes on Cox15 enzymatic function remains to be clarified
[139]. Of note, modeling of the R217W Leigh syndrome (LS)-associated substitution in yeast revealed
the mutation affects oligomeric properties of Cox15 [139]. In contrast to Cox10, the Cox15 active site
is predicted to reside on the IMS side of the IMM; no information is available as to how heme o is
transported across the IM to the Cox15 active site. Another riddle to this is the fact that eukaryotic
Cox10 and Cox15 do not stably interact [132] and are differentially regulated [135,139]. Unlike
COX10, COX15 gene expression is regulated by the transcription factor Hap1, which is itself
regulated by heme concentration [140]. As such, Cox15 protein levels are strictly regulated by heme
availability [135,139]. It has been suggested by studies of the bacterial Cox15 that the protein
contains a heme b cofactor [106], however, whether this proposed cofactor is necessary for enzymatic
function or maintaining protein structure has yet to be determined. There are four invariant
histidine residues in the protein, two in each of the domains. Mutation of any one of these residues
in bacterial species was found to ablate heme a [106]. Similarly, in the yeast Cox15, mutations in
these invariant histidine residues are critical for the enzyme’s function and cannot be substituted
with other heme-ligating amino acids [139]. The structural study by Niwa et al. [138] on B. subtilis
heme a synthase indicates that the N-terminal half domain of Cox15 is likely constitutes heme o
substrate binding site, whereas the C-terminal domain of the enzyme harbors a heme b cofactor
molecule. This structure also implicated an ultraconserved glutamate residue (Glu-57 in the bacterial
enzyme) as the catalytic residue [138]. However, the exact mechanistic role of these residues in
eukaryotic Cox15 remains to be validated.
In S. cerevisiae, the Cox15-catalyzed conversion of heme o to heme a is known to occur in
conjunction with the mitochondrial ferredoxin and ferredoxin reductase, yeast adrenodoxin
homolog 1 (Yah1) and yeast adrenodoxin reductase homologue 1 (Arh1), respectively [103–105,141].
The heme b moiety of Cox15 is likely a key cofactor for electrons supplied by this redox couple. Yah1
and Arh1 are mitochondrial [2Fe-2S] proteins that are important for the maturation of Fe/S proteins
[142,143]. Yah1 receives its electrons from Arh1, which utilizes NADH as its electron source. These
two proteins supply Cox15 with electrons and thus are critical for the formation of heme a [103,141].
Of note, in Schizosaccharomyces pombe Yah1 and Arh1 exist as portions of a tandem fusion protein
[144]. The yeast Yah1 functions as an electron donor for both heme a and iron-sulfur cluster
biosynthetic machineries, whereas mammalian mitochondria are equipped with two isoforms of
ferredoxin—FDX1 and FDX2—where FDX1 functions specifically in steroidogenesis and FDX2 is
specific for heme a and iron-sulfur cluster biogenesis [145].
3.3.3. Other Proteins Related to Heme a Biogenesis
Additional factors have been implicated in maturation and/or transport of heme a to its final
destination. This group of proteins includes CcO assembly factors Pet117, Shy1/SURF1 and the
yeast-specific protein Coa2.
Pet117 was identified as a conserved 107-amino acid-long CcO assembly factor by McEwen et al.
[146]. Since its discovery, little work has been done to characterize the protein. Deletion of the
PET117 gene was shown to have a reduction in heme a levels [147], indicating that Pet117 may
function in heme a biosynthesis in some manner. We recently showed that Pet117 is the
mitochondrial protein localized to the matrix side of the IMM [148]. More importantly, we
discovered that Pet117 stably interacts with Cox15; this interaction is independent of catalytic
function of Cox15, but deletion of the 20-amino acid unstructured linker region of Cox15 abolishes
the interaction. While Pet117 does not appear to be a heme-binding protein per se, its deletion results
in a loss of Cox15 oligomerization, indicating that Pet117 promotes stabilization of Cox15 oligomers,
thus facilitating heme a biosynthesis. Based on the observation that the Pet117-Cox15 interaction is
ablated in mitochondria lacking Cox1 transcriptional activator Mss51 [148], it is tempting to
speculate that Pet117 may be coupling Cox15 oligomers to maturing Cox1 assembly intermediate.
Shy1/SURF1 is a conserved IM-anchored CcO assembly factor whose exact function has yet to
be clarified. In both yeast and mammals, newly synthesized Cox1 progresses through a series of
intermediates containing different assembly factors. Formation of the heme a3:CuB bimetallic center
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appears to occur in an intermediate containing Shy1 [126,131][149]. It remains unclear, which Cox1
assembly intermediate triggers Cox10 and Cox15 activation and oligomerization [133]. Recent
reports indicate that Shy1 substoichiometrically associates with Cox15, so Shy1 is likely to play a
certain role in CcO hemylation [149]. Studies with recombinant Pseudomonas denitrificans SURF1
isoforms shown the protein can stoichiometrically bind heme a, leading to the conclusion that this
protein can act as a heme chaperone in Cox1 hemylation [150,151]. However, subsequent analyses of
Shy1/SURF1 in eukaryotes have challenged this postulate. Shy1 is partially dispensable as null
mutants retain a significant percent of CcO activity [152]. In the human Shy1 homologue, SURF1, the
same is true for several cases of the truncating SURF1 mutation [153]. In yeast, SHY1 mutants only
produce 10–15% of the fully functional CcO complex, similar to Leigh Syndrome (LS) patients who
exhibit 10–30% of normal CcO. Moreover, mutation of conserved candidate heme-ligating residues
had little to no effect on the protein’s function indicating that Shy1 is unlikely to be a dedicated heme
chaperone [152]. Shy1/SURF1 may thus be simply facilitating CcO hemylation by stabilizing the
maturing Cox1 subunit, but further analyses are warranted to validate this model.
Coa2 is an assembly factor for CcO in yeast, originally identified as a high-copy genetic
suppressor of the shy1 mutation [154]. This small (~11 kDa), matrix-localized protein functions
downstream of insertion of newly synthesized Cox1 into the IM and it has been shown to physically
interact with Shy1 [154]. The newly synthesized Cox1 is rapidly degraded in the absence of Coa2,
presumably due to impaired hemylation and misfolding of this CcO subunit [132,154,155]. Just like
Shy1/SURF1, Coa2 does not appear to be a bona fide heme chaperone, but its deletion affects
oligomerization of both Cox10 [132,133] and Cox15 [133]. Interestingly, our data suggest that unlike
Cox10, Cox15 still oligomerizes in coa2∆ cells, but that the complex is more labile and collapses
under blue native electrophoresis conditions (our unpublished data). This indicates that Coa2 is
likely not required for Cox15 oligomerization but plays more of a stabilizing role for Cox15
oligomers, similar to the Pet117 protein. As mentioned previously, the respiratory defect of
coa2cells is specifically suppressed by the dominant gain-of-function N196K mutation in Cox10
[132] or—to much lesser extent—by the enhanced Cox1 synthesis [133]. Consistent with Coa2’s role
in HOS oligomerization, both suppression mechanisms are associated with the abundance of Cox10
oligomer. These observations led to a conclusion that Coa2 may be important for coupling Cox1
synthesis to Cox15 oligomerization and/or activity [133]. An outstanding question remains if such
principles can be applied to mammalian heme a transport, as it is currently unclear whether a
human homolog of Coa2 exists.
3.4. Heme c and Heme a Pathway-Related Diseases
Several human diseases stem from defects in heme c and heme a pathways. The hereditary
dominant microphthalmia with linear skin defects (MLS) syndrome-associated mutations in HCCS
have been linked to both defective heme binding and cytochrome c release, highlighting the
importance of these processes to human physiology [156,157]. These findings also strongly suggest
that heme binding to CCHL proteins is a rate-limiting step in cytochrome c maturation.
Mutations in conserved residues of Cox10, Cox15 and SURF1 manifest in tubulopathy and
leukodystrophy [158], sensorineural deafness [159], fatal infantile hypertrophic cardiomyopathy
[159–161], Charcot-Marie-Tooth disease type 1A [162] and neurologic LS [153,159,163–170]. Of note,
pathologic mutations in SURF1 account for the majority of cases of LS associated with CcO
deficiency [171].
The yeast Pet117 has a human orthologue that is approximately 81 amino acids in length and
that has not been thoroughly studied. One study proposed that human PET117 might be involved in
copper insertion to CcO [172]. However, more recent reports have challenged that idea. In addition
to our study in yeast, a premature stop codon patient mutation in PET117 has been identified [173].
This mutation results in a LS-like condition from complex IV deficiency—reduction in steady state
levels of complex IV as well as the core subunits, Cox1–3 and reduction in complex IV activity levels.
Treatment of patient fibroblasts with exogenous copper was unable to rescue the complex IV
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deficiency, indicating that PET117 likely does not function as a copper chaperone [173]. The role of
PET117 in heme a biosynthesis in humans has yet to be clarified.
4. Extra-Mitochondrial Heme Trafficking
Cellular heme is either derived endogenously from de novo synthesis or exogenously from
heme uptake (Figure 4) [2,3,174]. Once synthesized by FECH or transported into the cell, heme must
be mobilized and delivered to heme-dependent proteins residing in virtually every subcellular
compartment. As with other transition metals, e.g., copper or iron, it is generally assumed that heme
distribution is mediated by the coordinated action of heme transporters, chaperones and carrier
proteins [2,3]. However, unlike other transition metals, heme is also a hydrophobic lipid-like
molecule [3]. This raises the possibility that heme could be trafficked like other mitochondrial
derived lipids via vesicles or through contact sites between organelles. In this section, we highlight
our current understanding of the journey heme takes from its site of synthesis or uptake to locations
throughout the cell.

Figure 4. Schematic representation of heme trafficking within a eukaryotic cell. Heme synthesis is
completed within the matrix of the mitochondria; from here heme (red polygons) is mobilized
throughout the cell to the cytosol, IMS, peroxisome, lysosome, endoplasmic reticulum (ER), Golgi,
nucleus and extracellular space. Known heme buffering factors and transporters are highlighted, any
unknown pathways are marked with question marks.

4.1. Exit of Mitochondrial Heme
How is heme trafficked out of the mitochondria? One possibility is that it is exported via
dedicated heme transporters (Figure 4). The only mitochondrial heme transport protein identified to
date is Feline leukemia virus subgroup C receptor-related protein 1b (FLVRC1b), a member of the
major facilitator superfamily (MFS) of secondary active transporters [175]. FLVCR1b is a six-TMD
protein that is derived from an alternative transcriptional start site located within the first intron of
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Flvcr1 [175], which otherwise encodes FLVCR1a, a twelve TMD plasma membrane heme exporter
[14,176]. The primary evidence of the role of Flvcr1b in mitochondrial heme export stems from
over-expression and depletion studies; silencing of Flvcr1b transcript using siRNA results in
mitochondrial heme accumulation and termination of erythroid differentiation while
overexpression results in increased cytosolic heme [175]. While the genetic evidence for the role of
Flvcr1b in heme export is quite strong, there are a number of unresolved questions. For instance,
there is still no direct biophysical evidence that Flvcr1b can transport heme or mechanistic
understanding of heme translocation. Interestingly and quite importantly, a segment of Flvcr1a
found to be important for heme binding and transport, e.g., residues 132–201 and in particular
His-145, Tyr-153 and His-198, are missing in Flvcr1b [177]. Additionally, it is not known whether
Flvcr1b is located on the inner or outer mitochondrial membranes, which will have implications for
where it acquires and transports heme, i.e., matrix to IMS vs. IMS to cytosol. In the context of the
heme metabolon, it is tempting to speculate that Flvcr1b could interact with FECH or other
components of the heme biosynthetic machinery and accept heme for transport immediately upon
its synthesis. However, data from affinity purification studies of FECH do not support this
interaction [82].
Affinity purification data do support interactions between FECH, PGRMC1 and PGRMC2 [83].
Both PGRMC1 and PGRMC2 have been proposed to be heme chaperones [90,178,179]. As mentioned
earlier PGRMC1 and PGRMC2 are both proteins that bind heme with moderate affinity and either
stimulate hemoproteins including cytochrome P450s [87–89] or alter labile heme levels in different
cellular compartments [90]. Interestingly PGRMC1 has been localized to multiple cellular locations
including the ER [180], mitochondria [83], nucleus [181] and cellular membrane [182], while
PGRMC2 is an ER protein [90]. Multiple studies have found that PGRMC1 and PGRMC2 interact
[90] and recent studies using adipose-tissue specific knock out of PGRMC2 or both PGRMC2 and
PGRMC1 result in nuclear heme homeostasis disruption and metabolic dysfunction [3]. Thus,
PGRMC1 and PGRMC2 have been proposed to function as a conduit for heme transport from FECH
in the mitochondrial matrix to the ER and nucleus [90]. Further studies of these proteins will shed
light of the mechanisms by which these proteins function in cellular heme trafficking.
Instead of heme export from the mitochondria via a single transport protein, there are likely
multiple routes of heme export. Indeed, S. cerevisiae does not encode Flvcr1 homologs and has a
single PGRMC1 and PGRMC2 protein (Dap1), implying the presence of alternative heme transport
mechanisms (Figure 4). In addition to other yet to be determined heme transporters, alternative
pathways for mobilizing mitochondrial heme involves its passage through membrane contact points
or vesicular trafficking to other organelles [3]. With respect to the former, there may be direct heme
transfer between the mitochondrial and ER networks via mitochondria-associated membranes
(MAMs). MAMs form a contiguous interface between the mitochondrial outer-membrane and the
endoplasmic reticulum (ER) via the ER-mitochondria encounter structure (ERMES). While ERMES
has previously been implicated in facilitating the exchange of lipids between the ER and
mitochondria, it may also serve as a route for heme transfer as well [183]. While direct evidence for
the role of MAMs and ERMES in facilitating heme exchange is lacking, it is worth noting that a
number of heme homeostatic factors, including CPOX, FECH, heme-binding protein 1 (HBP 1),
heme oxygenase-2 (HO-2) and PGRMC1 have been found to associate with MAMs [184,185]. Since
the ER network extends between the nucleus, Golgi and secretory pathway, once heme exchanges
into the ER, it can bind to any number of hemoproteins present in these locations, as well as proteins
that are eventually secreted or are directed to the lysosome, peroxisome, or plasma membrane.
However, the mechanisms underlying heme distribution in the ER or Golgi are currently unknown.
Another potential mechanism for the export of mitochondrial heme is via mitochondrial-derived
vesicles (MDVs) [186]. MDV’s have been found to traffic material to peroxisomes and lysosomes and
it is possible that heme may also be packaged in these vesicles as cargo.
4.2. Import of Exogenous Heme
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Heme can be acquired from exogenous sources in addition to de novo synthesis. As with
mitochondrial heme export, heme import could be mediated by a number of different mechanisms,
including transporters, hemoprotein receptors, endocytic pathways or lipid carriers (Figure 4). The
first bona fide eukaryotic heme transporters, HRG-1 and HRG-4, were identified using molecular
genetic approaches in Caenorhabditis elegans. As a heme auxotroph, all heme in C. elegans is derived
from nutritional sources and is mobilized from the intestines to tissue throughout the animal [187].
Heme responsive genes HRG1 and HRG4 were first identified from a transcriptomic screen as genes
that are up-regulated during growth on low heme and were later determined to be involved in
intestinal heme uptake in worms [188]. HRG-4, which lacks mammalian homologs, localizes to the
plasma membrane, while HRG-1, which is conserved from arthropods to vertebrates, including
mammals (20% identity between human and C. elegans HRG1), is present in endosomes and
transports exogenously-derived heme into the cytosol.
Human HRG1 is predicted to have four TMD-spanning helices [188,189] and functions
cooperatively with a V-type H+-ATPase. Indeed, acidification of endosomes is necessary to protonate
heme coordinating residues of hemoproteins to facilitate the release of heme, solubilize unbound
“free” heme and couple heme export out of endosomes to a proton gradient [189]. A number of lines
of evidence have implicated HRG1 as a heme transporter, including (i) HRG-1-mediated import of
heme into Xenopus oocytes; (ii) HRG-1-mediated transport of zinc mesoporphyrin (ZnMP) into the
C. elegans intestine and ectopically expressing murine cells; and (iii) HRG-1 heme transport activity
using yeast reporter assays. Furthermore, a number of highly conserved heme-binding His and Tyr
residues are critical for HRG1 activity [190]. Functionally, HRG-1 is critical for mobilization of heme
from the phagolysosome of macrophages during erythrophagocytosis [191] and heme uptake and
utilization in the C. elegans intestine [188].
An additional putative cell surface heme transporter is FLVCR2 [192]. Indeed, FLVCR2 binds to
hemin-agarose, FLVCR2 overexpression in Chinese hamster ovary (CHO) cells and Xenopus laevis
oocytes leads to accumulation of exogenous heme and enhanced sensitivity to heme toxicity and
FLVCR2 depletion by siRNA leads to reduced accumulation of the fluorescent heme analog, zinc
mesoporphyrin. On the other hand, unlike HRG-1 and HRG-4, when FLVCR2 is expressed in a yeast
system, it cannot transport heme to rescue heme-deficient strains [190]. Furthermore, while there is
no clear physiological role for FLVCR2 in regulating heme homeostasis in vivo, it is interesting to
note that Fowler syndrome, a vascular disorder of the brain that is caused by mutations in FLVCR2,
is associated with defects in the activity of heme-containing respiratory complexes [192].
Another mechanism of heme import is via the uptake of hemoproteins. Haptoglobin and
hemopexin, a pair of serum heme-scavenging proteins, bind to hemoglobin and heme, respectively
released during hemolysis or cellular injury. Haptoglobin, which is secreted from hepatocytes, binds
plasma hemoglobin with high affinity, KD ≈ 10−12M [193] and this complex is endocytosed by
macrophages via the receptor CD163 [194]. The heme from hemoglobin is subsequently released
during endosomal acidification and imported into the cytoplasm and recycled by macrophages
[195]. Hemopexin, which is primarily produced by the liver, binds “free” heme in the plasma with
high affinity, KD ≈ 10−13M [196] and this complex is endocytosed via the LRP1/CD91 receptor [196–
198]. While LRP1 clearly plays a role in heme catabolism in the liver, its presence and role in cells
other than hepatocytes is unclear and suggests it may function in heme uptake for utilization or as a
source of iron [198].
In addition to heme transporters and receptor-mediated endocytosis of hemoproteins, heme
uptake may also be mediated by the endocytosis of heme-loaded microparticles derived from red
blood cells [199–202]. Although typically associated with red blood cell storage lesions or sickle-cell
disease, circulating erythrocytes can release heme-laden microparticles that are highly
inflammatory. These particles are endocytosed by endothelial cells in a Rab5-dependent manner
[203] and constitute an additional mechanism of heme uptake by cells.
Another mechanism for the uptake of extracellular heme in mammals involves its sequestration
by lipoprotein particles that can subsequently be endocytosed [101]. Free heme has the capacity to
partition into low-density lipoproteins (LDLs) and high-density lipoproteins (HDLs) despite the
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presence of heme-scavenging proteins haptoglobin, hemopexin and albumin [101]. Once
internalized, lipoproteins can release heme from acidic endosomal compartments. Altogether,
multiple mechanisms account for the cellular import of exogenous heme for utilization or
catabolism. Pathways for the endocytosis of exogenous heme have been identified in yeast as well,
including budding and fission yeast, S. cerevisiase and S. pombe, respectively. In S. cerevisiase,
FECH-depleted hem15∆ cells can be rescued by heme in fermentable media but not in
non-fermentable media while cells are respiring [204,205]. The mechanism by which yeast cells
import exogenous heme and the basis for why mitochondrial heme import is inefficient is not
completely clear. A recent study identified gain-of-function mutant variants of the plasma
membrane protein Nce102 as a genetic suppressor of respiratory defects in heme-supplemented
hem15 mutants [83]. While the exact suppression mechanism remains elusive, the eisosome
complex-related Nce102 [206] is likely to facilitate the uptake of exogenous heme via the endocytic
pathway, wherein direct short-lived interactions between endosome and mitochondria mediate
heme transfer between these subcellular compartments. In S. pombe, exogenous heme is endocytosed
and trafficked to the vacuole for storage in a manner dependent on internalization by Shu1, a cell
surface receptor and vacuolar transport by the ESCRT pathway [207–210].
4.3. Exogenous vs. Endogenous Heme
A long-standing dogma in heme cell biology field is that the cellular heme quota is solely
dictated by de novo synthesis and degradation; any imported exogenous heme is thought to be
degraded by heme oxygenases (HO) and the released iron is siphoned for de novo heme synthesis,
stored, or utilized for any number of other iron-dependent processes. However, two major
challenges to this paradigm are that: (i) heme supplementation rescues a number of cell and animal
systems that are defective in heme synthesis, suggesting exogenous heme may in fact be recycled
and reused independently of heme degradation [187,211,212]; and (ii) heme exporters [13,14] and
inter-cellular heme chaperones [213] have been identified, which strongly suggests that heme can be
shared between cells. Taken together, these new findings have prompted us to re-think the
traditional paradigm that all heme for use in metabolism is derived from de novo synthesis in the
mitochondria. However, the relative contributions of endogenously synthesized heme and
exogenously supplied heme to cellular heme pools need to be determined. Further, there is little
understanding of how imported heme is trafficked for degradation by HO in the ER or how cells
bifurcate the flow of exogenous heme between HO and other heme-dependent processes.
A wealth of data indicates exogenous heme may be utilized in toto independently of its
degradation. In the unicellular model eukaryote, yeast S. cerevisiae, hem1∆ cells, lacking the first
enzyme in the heme synthesis pathway, ALA synthase, can be rescued to some extent by heme
supplementation [204,205]. Further, in humans, patients suffering from certain porphyrias, a class of
disorders characterized by heme synthesis defects, can be treated with intravenous heme and
heme-albumin, which rescues heme-dependent enzyme activities in various tissues [214]. However,
it is unclear how imported heme is distributed for use in metabolism in a manner that bypasses HO
or what the mechanisms of heme uptake are for the mitochondria and other subcellular
compartments. Interestingly, using horseradish peroxidase activity-based heme reporters targeted
to different subcellular compartments in HEK293 cells, it was determined that exogenous and
endogenous heme is trafficked differently to various subcellular compartments [174]. However, the
mechanisms underlying the hierarchical distribution of exogenous and endogenous heme to various
cellular locales are unknown.
What are the mechanisms underlying the mobilization of heme out of the cell and what is the
rationale for such a process? FLVCR1a is a 12 TMD plasma membrane heme export protein of the
major facilitator superfamily of transporters. FLVCR1 was first discovered as a receptor for feline
leukemia virus (FeLV) and its involvement in heme homeostasis was established based upon the
development of aplastic anemia due to a loss of erythroid progenitors upon FeLV infection. It was
subsequently determined that FLVCR1a is a cytoplasmic heme exporter that protects developing
erythroid cells from heme toxicity and susceptibility to anemia [14,176]. As mentioned earlier, it was
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later determined that an alternative transcriptional start-site located within the first intron of
FLVCR1a results in a shorter transcript that produces a truncated 6 TMD isoform, FLVCR1b, which
transports heme out of the mitochondria [175]. Further, another FeLV receptor, the homologous cell
surface protein, FLVCR2, was implicated as a heme importer [192].
FLVCR1a is thought to primarily protect cells from heme toxicity. For instance, it is thought that
FLVCR1a exports heme from macrophages during erythrophagocytosis of senescent red blood cells.
In fact, FLVCR1a interacts with hemopexin, an extracellular heme scavenger and exports heme >
100-fold more efficiently in the presence of hemopexin [215]. Further, FLVCR1a protects developing
red blood cells from heme toxicity by acting as a safety valve to export potentially cytotoxic heme. In
addition to its role in protecting cells from heme toxicity, there may also be inter-cellular signaling
functions for heme. For instance, as a pro-inflammatory signaling molecule, erythrocyte-derived
heme can differentiate and activate macrophages for clearance of red blood cells [15].
In addition to FLVCR1a, another mechanism for cellular heme export involves MRP-5, an ABC
transporter (Figure 4) [216]. Loss of MRP-5 leads to embryonic lethality in C. elegans that can be
rescued by addition of exogenous heme. Further, Mrp5 deficient mice have reduced heme levels in
the secretory pathway of embryonic fibroblasts. However, Mrp5−/− mice do not show overt
heme-related phenotypes, possibly due to compensation by other ABC-transporters. Taken together,
like FLVCR1a, MRP5 provides yet another conduit for heme export from the cell; though its precise
physiological function is unclear. Yet another protein shown to be involved in heme export is
ABCG2, also known as the breast cancer resistance protein (BRCP). ABCG2 is an ATP-binding
cassette transporter which has been shown to transport heme, hemin and porphyrin in addition to a
variety of medications [217–221]. ABCG2 is expressed by a variety of normal tissues including
placenta, brain, small intestines, ovary, liver and hematopoetic stem cells, as well as in a number of
cancer cells [222]. Recent studies have shown that ABCG2 exports heme to serum albumin and that it
functions in cellular protection [217]. While these export proteins suggest a protective function by
which heme or porphyrin that is overexpressed or accumulated is exported for catabolism, such a
process seems wasteful and potentially dangerous to the organism.
Another route for heme mobilization from cells is through secreted hemoproteins. In C. elegans,
HRG-3, a 8 kDa intercellular heme chaperone protein, binds and delivers maternal heme to
developing oocytes [213]. These results suggest that heme can be transferred between tissues and
cell types as a nutritional heme source. However, the degree to which this happens in higher animals
during development is unclear. Altogether, the identification of heme export pathways and heme
rescue of phenotypes associated with defects in heme synthesis suggests heme can be utilized for
metabolism independently of heme catabolism pathways.
4.4. Heme Trafficking Factors
The factors that regulate heme bioavailability and distribution are poorly understood.
Historically, biochemically driven approaches toward probing heme homeostatic mechanisms and
defining the heme proteome have been instrumental. For instance, cellular heme-binding proteins
(HBPs) have been identified on the basis of their interaction with heme-agarose or blue-sepharose.
These HBPs include 22 kDa HBP, 23 kDa HBP, SOUL, glutathione-S-transferase, fatty acid-binding
protein (FABP) and glyceraldehyde phosphate dehydrogenase (GAPDH) [2,3,223]. However, with
the exception of GAPDH, it is not known what role these HBPs play in regulating heme homeostasis.
GAPDH was not only found to regulate heme insertion into nitric oxide synthase in a
NO-dependent manner [224], but also found to buffer cytosolic heme and regulate its availability to
a nuclear heme regulated transcription factor [91,92].
5. Multi-Model Comparison of Eukaryotic Heme Homeostasis
All heme-requiring organisms occupy a position on the continuum between relying exclusively
on de novo heme synthesis and heme uptake. Most eukaryotes, including mammalian cells, are in
the middle of this continuum and can both import and synthesize heme efficiently [174]. As
mentioned previously, organisms like C. elegans, rely exclusively on heme uptake from nutritional
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sources and cannot make their own heme due to the lack of a functioning heme biosynthetic
pathway [187]. As an interesting aside, these nematodes retained a pseudo FECH protein, encoded
by the gene fechl-1 (accession code: K07G5.6), with 23% identity to mammalian FECH. While this
protein is expressed, it lacks canonical FECH activity [187,225,226]. Several other organisms
including the cattle tick Rhipicephalus (Boophilus) microplus [227] and the Atlantic salmon louse
Lepeophtheirus salmonis [228] are heme auxotrophs as well. S. cerevisiae, on the other hand, is not
efficient at importing heme and is almost exclusively reliant on heme synthesis [211]. Since much of
our current understanding of eukaryotic heme homeostasis comes from work in Baker’s yeast,
mammalian cell lines and C. elegans, we have a window into common and divergent themes in heme
homeostatic pathways of organisms that occupy different positions on the continuum of heme
acquisition between synthesis and uptake (Table 1).
First, if an organism can make heme, eukaryotic heme synthesis is highly conserved and all
eight heme biosynthetic enzymes share a high degree of homology across eukaryotic species.
Second, all eukaryotes have the capacity to export heme, but with divergent mechanisms. For
instance, Baker’s yeast expresses Pug1, a porphyrin-heme exchanger that imports PP IX while
exporting heme [211]. On the other hand, in the model metazoan, C. elegans, intestinal heme is
shared via a secreted hemoprotein, HRG3, that delivers heme to other tissues. In vertebrates, the
heme transporter, FLVCR1a, is used to export heme into the extracellular space. On the basis for its
conservation between worm and man, one mechanism that may be common for heme export is
secretion via the secretory pathway, as proposed for MRP5-mediated heme export. Third, the import
of heme is generally poorly defined across eukaryotes. While cell surface heme importers are known
for C. elegans, e.g., HRG4, this factor is not well conserved in lower or higher eukaryotes. For
instance, it is still not known what the high affinity heme importer is for mammalian cells or even if
there is one. On the other hand, low affinity heme uptake factors like FLVCR2 and the folate
transporter, HCP-1, have previously been identified in mammalian cells [3]. Fourth, the factors that
mediate intracellular heme trafficking are largely unknown in any eukaryote. Two exceptions are
GAPDH [91,92,224] and PGRMC1/2 [89,90], which are the only factors found to play roles in
intracellular heme trafficking in both yeast and human cells lines, albeit their molecular mechanisms
are not known. Overall, while heme synthesis is highly conserved across all of eukaryotic life, the
transport and trafficking of heme is not and likely reflects the unique ecological niches that life
adapted to in order to acquire heme and control its bioavailability.
6. New Methods to Probe Heme Trafficking
Total heme in the cell can be considered to be a sum of exchange-inert and exchange-labile
pools [2]. Exchange-inert heme corresponds to heme buried in the active sites of high affinity
hemoproteins, e.g., globins and cytochromes and is not readily exchangeable. On the other hand,
exchange-labile heme can readily exchange between proteins and defines the bioavailable pool
relevant to heme trafficking and signaling. Until recently, there were no methods to monitor
bioavailable heme in intact living cells and most measurements simply reported “total” heme or the
most highly absorbing and/or abundant hemoproteins (Table 2). As a highly colored pigment,
historically, most measurements of heme from cell and tissue extracts involve the use of UV-visible
absorbance spectroscopy. Indeed, heme exhibits Soret band extinction coefficients between ~30,000
cm−1 M−1 and ~200,000 cm−1 M−1 in the 390–420 nm spectral region, depending on oxidation state and
the nature of coordinating protein ligands [136]. In samples with low turbidity, including body
fluids like plasma, heme can readily be quantified from UV-vis spectroscopy. In addition, since the
spectral characteristics of heme are sensitive to the identity of coordinating ligands and heme iron
oxidation state, spectral deconvolution can resolve free non-proteinaceous heme from hemoglobin
(Hb) [229]. Moreover, oxyHb and metHb can be readily differentiated as well [229]. However, due to
light scattering in many biological matrices, including cells and tissues, heme is often extracted using
strong acid, which serves to dissociate heme from proteinaceous ligands and organic solvents like
acetone or butanol, which separates heme from the aqueous phase [230]. Extracted heme can be
chromatographed by high performance liquid chromatography (HPLC) using a reverse-phase C18
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column coupled to an in-line UV-vis detector for quantification [231,232]. This method allows for
differentiating heme b from other heme types, including heme o or heme a [233]. Alternatively,
extracted heme or heme from soluble lysates or isolated hemoproteins may be quantified using the
pyridine hemochromagen assay, which is based upon the distinct spectral features of the
bis-pyridine ferrous heme complex [234–237]. The development of commercial instrumentation to
measure absorbing species in turbid samples, including in cells and tissues, has greatly facilitated
the measurement of heme in biological matrices. The Olis CLARiTY UV-vis spectrophotometer
employs a quartz cuvette within an integrating cavity absorption meter (ICAM) [237]. The quartz
cuvette contains a reflective coating that effectively increases the path length, making the instrument
much more sensitive to absorption of light in turbid samples [237,238]. Finally, the measurement of
porphyrin fluorescence is a very sensitive technique for the quantification of heme, with a limit of
detection of 10−9M [232,233]. While heme itself is non-fluorescent, de-metallation of the heme iron in
boiling oxalic acid results in the formation of fluorescent PP IX free base (λex = 400 nm; λem = 662 nm)
[232,233].
Table 2. Approaches to measure total and labile heme in cells and tissues. References are in the text.
Approaches

In Situ Label Free
Imaging

Methods

Advantages

Transient Absorption

Subcellular resolution (< 1

Microscopy

μm)

Resonance Raman Imaging

Non-invasive

2 Photon Photothermal Lens

Can probe heme dynamics

Microscopy

in living cells

Subcellular resolution (< 1
μm)
In Situ Imaging of Labile

HS1

Direct probe of labile

Heme using Fluorescent

CISDY-9

“bioavailable” heme

Heme Sensors

CHY

Can probe heme dynamics
in living cells
High-throughput

Disadvantages
Signals dominated by most
abundant and/or highly
absorbing species
Low-throughput
Requires specialized
equipment/expertise
May perturb heme
homeostasis
Possible selection bias
depending on the nature of the
sensor
Extended time resolved
studies precluded by
photobleaching

Horseradish Peroxidase
Tryptophan 2,3 Dioxygenase
Assays for Endogenous
Markers of Heme
Bioavailability

(TDO)

Measurement of heme

Disruption of cells and tissues

Indoleamine-2,3-Dioxygenase

accessible to endogenous

Time consuming

(IDO)

hemoproteins

Difficult to get fast time

Cytochrome P450

No genetic perturbations

resolution

Catalase
Transcription Factors

Assays for Total

HPLC

Heme
Porphyrin Fluorescence
UV/vis

CLARiTY

Resolve different heme
types
nM sensitivity
High-throughput
Sensitive measurements in

Time consuming
Disruption of cells and tissues
Low-throughput
Disruption of cells and tissues
Signals dominated by most
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Absorbance

turbid samples

abundant and/or highly

Spectroscopy

Possible to measure heme

absorbing species

and hemoproteins in

Low-throughput

intact cells

Requires specialized
equipment

Pyridine Hemochromagen

Broadly accessible
Inexpensive

Disruption of cells and tissues

Although the aforementioned methods serve as powerful tools for measuring heme, they suffer
from a number of drawbacks. First, these methods often rely on cell and tissue disruption and
homogenization, which is time consuming, technically demanding and may result in the loss of
heme from the samples. Second, they do not provide information on heme distribution and
localization, unless great care is taken to isolate organelles and subcompartments. Third, these
methods do not resolve heterogeneity within populations of cells or the spatio-temporal dynamics of
heme. Fourth, these methods fail to resolve the differences between total and bioavailable heme, the
latter of which defines the pool of heme accessible for all heme-dependent functions.
Traditional methods to probe heme bioavailability involve assaying the activities of various
heme-dependent enzymes and transcription factors in cell or tissue extracts, including cytochrome
P450 enzymes (ER) [239,240], catalase (peroxisomes or mitochondria) [92,241], tryptophan 2,3
dioxygenase (cytosol) [242], indoleamine-2,3-dioxygenase (cytosol) [243], various nuclear
transcription factors, e.g., Hap1 (in yeast), Bach1, p53 and Reverb-α/β [2,3,92,241] and peroxidases
that can be genetically encoded and targeted to different subcellular compartments [174,244] (Table
2). While these methods have shed considerable insight into heme homeostatic mechanisms, they
suffer from a number of drawbacks that arise from harsh lysis conditions and time-intensive enzyme
assays. Therefore, these enzymatic assays may artifactually alter bioavailable heme pools due to the
repartitioning of heme upon cell lysis and are unsuitable for probing the spatial and temporal
dynamics of cellular heme due to the challenges associated with rapidly isolating organelles.
More recently, the development of genetically encoded fluorescent heme sensors has
revolutionized the ability to image and probe labile heme relevant to its trafficking and signaling in
intact living cells and subcellular compartments, circumventing the need for cell disruption and
time-intensive enzyme assays. Independently and virtually contemporaneously, three labs reported
the development of genetically encoded ratiometric fluorescent heme sensors. Song et al., [245]
reported the first FRET sensor for cellular heme imaging. The sensor, CISDY, consists of a heme
sensing moiety containing NEAT domains of a pair of heme transfer chaperones, IsdX1 and IsdC,
tethered by a linker and flanked by enhanced cyan and yellow fluorescent proteins (ECFP and
EYFP) at the N and C terminus, respectively. Heme binding induces the dimerization of IsdX1 and
IsdC, resulting in an increase in the FRET efficiency between ECFP and EYFP. Expression of CISDY
across various human cell lines and in locations spanning the cytosol, nucleus, mitochondria and ER,
revealed labile heme to be ~20 nM in all these compartments.
Following this development, Hanna et al., [92] reported the FRET-based heme sensor 1 (HS1), a
fusion of cytochrome b562 (Cyt b562), enhanced green fluorescent protein (EGFP) and a red fluorescent
protein, Katushka 2 (mKATE2). Heme binding to Cyt b562, a His/Met heme-binding protein from E.
coli [246], results in > 90% quenching of EGFP fluorescence via FRET. mKATE2, on the other hand, is
a poor FRET donor to heme [92] and its fluorescence is relatively insensitive to heme binding to the
Cyt b562 module. Thus, the ratio of heme-sensitive EGFP fluorescence to heme-insensitive mKATE2
fluorescence provides a readout of cellular heme. The application of HS1 has uncovered
fundamental insight into heme trafficking, dynamics and signaling. For instance, the HS1 variant,
HS1-M7A, was used to screen the yeast gene deletion collection to identify genes that regulate heme
bioavailability. One factor that was identified to regulate heme bioavailability and trafficking to a
nuclear heme-regulated transcription factor was the glycolytic enzyme, GAPDH [241]. Further,
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using HS1-M7A, it was found that subcellular heme pools are highly dynamic and can be mobilized
by signaling molecules like nitric oxide (NO) [92] and heavy metal stress [241].
Even more recently, Abshire et al. [247] reported a FRET-type sensor consisting of the
Plasmodium falciparum histidine-rich heme-binding protein 2 (PfHRP2) flanked by ECFP and EYFP as
FRET donor and acceptor proteins, respectively. Heme binding to PfHRP2 results in a lowering of
the fluorescence lifetime of ECFP due to energy transfer to the heme moiety and therefore a decrease
in FRET between ECFP and EYFP. While the heme sensor domain non-cooperatively binds ~15–18
heme molecules/monomer with an apparent dissociation constant of ~0.3 μM, a “mini-library” of
sensor variants results in sensors with varying heme-binding stoichiometries, ~5–15 and heme
dissociation constants, 0.05–0.25 μM. Using these sensors in the malaria parasite, it was found that P.
falciparum maintains the cytosolic labile heme pool at ~1.6 μM throughout its development in red
blood cells. Further, it was found that anti-malarial drugs that target heme homeostatic mechanisms
in P. falciparum, including chloroquine, significantly increase labile heme. Altogether, the advent of
ratiometric fluorescent heme sensors has greatly expanded the tools available to probe heme
homeostatic mechanisms and mobilization dynamics in health and disease in an unprecedented
manner.
However, one potential drawback with the aforementioned heme sensors is that their
expression may itself perturb heme homeostasis due to heme sequestration [2]. Moreover, different
sensor scaffolds may access different heme pools due to kinetic constraints associated with heme
exchange. Thus, measurements of labile or bioavailable heme may in effect be a sensor-dependent
parameter. Due to these potential issues, measurements of bioavailable heme with heme sensors can
be complemented by label-free heme imaging modalities that exploit the rich electronic and
vibrational transitions of metalloporphyrins, including resonance Raman, photothermal lens and
transient absorption microscopies (Table 2). Resonance Raman is a vibrational spectroscopy in
which incident radiation from a laser that is resonant with an electronic transition of a target
molecule is inelastically scattered upon excitation of various vibrational transitions [248]. The
difference in energy of the incident radiation and the scattered photons is diagnostic of the specific
molecules being excited and their local environment. In particular, resonance Raman has been used
for decades to characterize the coordination environment of heme in various hemoproteins. In
resonance Raman microscopy, resonance Raman spectroscopy is coupled with microscope optics to
generate a “Raman map” that gives structural and chemical information with spatial resolution
[249]. This method has been utilized to probe the activity of a number of hemoproteins in living cells,
including NADPH oxidase activity in neutrophils and hemoglobin oxygenation in erythrocytes.
Moreover, it was used to probe hemoglobin and hemozoin distribution during erythrocyte infection
with P. falciparum [250].
Photothermal microscopy relies on the detection of local heating generated by optical
absorption of molecules. When combined with two-photon excitation using longer wavelength light
to excite a chromophore rather than one-photon linear absorption, there is a decrease in scatter,
background signal and photo-bleaching with increased sample penetration depth. Heme is an ideal
candidate for the use of two-photon photothermal lens microscopy as it absorbs strongly and is not
fluorescent [251,252]. Using photo-thermal lens microscopy, the distribution of hemoproteins,
including globins and cytochromes, in cell and tissue samples was measured in situ.
Transient absorption microscopy (TAM) utilizes ultra-fast pulsed lasers to measure the excited
state dynamics and spatial distribution of chromophores [253]. A “pump” laser is used to excite an
absorbing species and a “probe” laser is used to measure the excited state dynamics of that molecule.
The excited state dynamics are diagnostic of particular chromophores and can reveal the chemical
nature and environment of a molecule [254]. Transient absorption microscopy is efficient at
quantifying and visualizing chromophores, especially those that have low quantum yields [255].
TAM has been utilized to observe heme in frozen heart tissues as well as heme distribution and
dynamics in C. elegans [253,256].
The major advantage of these methods is that samples do not need to be derivatized or
genetically altered and heme can be probed in situ, ensuring that heme homeostasis and cellular
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metabolism is not perturbed. However, a limitation is that the spectroscopic features being probed
may be derived from a complex heterogeneous mixture of heme species, making the deconvolution
and interpretation of signal changes challenging. On the other hand, in cell types where the signal is
dominated by a few abundant and/or highly absorbing heme complexes, e.g., hemoglobin in red
blood cells, the application of such label-free techniques may be simpler to interpret. Altogether, the
new heme sensors and label-free imaging of heme provide a new set of tools to further define the
exciting questions related to heme trafficking in living intact cells.
7. Concluding Remarks
Heme is a versatile biological molecule of paramount importance for cellular physiology.
Because of its involvement in virtually all aspects of aerobic life and high relevance to human health
and pathology, this fascinating metallo-organic compound and its complex metabolism have been
extensively studied. In spite of over six decades of heme research, many gaps in our understanding
of cellular heme metabolism still remain. For example, the mechanisms that heme b uses to shuttle
away from FECH and to route to its sites of utilization across the cell are only beginning to emerge.
Development of novel models, tools and methods to quantitatively study trafficking of heme and its
precursors in vivo is highly promising and likely will continue gaining some exciting new insights
into the mechanisms behind heme transport and distribution within eukaryotic cells. Deciphering
how heme is routed within and outside mitochondria as well as regulatory aspects of these
processes will provide answers to a number of outstanding biological questions and contribute
towards greater understanding of highly prevalent heme-related pathologies.
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CO, carbon monoxide; IMS, mitochondrial intermembrane space; TCA, tricarboxic acid; IMM, inner
mitochondrial membrane; 5-ALA, 5-aminolevulunic acid; ALAS, aminolevulunic acid synthase; PBGS,
porphobilinogen synthase; PBG, porphobilinogen, HMB, hydroxymethylbilane; HMBS, hydroxymethylbilane
synthase; UPgen III, Uroporphyrinogen III; UROS, uroporphyrinogen synthase; CPgen III, coproporphyrinogen
III; UROD, uroporphyrinogen decarboxylase; PPgen IX, protoporphyrinogen IX; CPOX, coproporphyrinogen
oxidase; Fe-PPIX, iron-protoporphyrin IX; PPIX, protoporphyrin IX; PPOX, protoporphyrinogen oxidase;
FECH, ferrochelatase; PLP, pyridoxal 5’-phosphate; OMM, outer mitochondrial membrane; SLC, Solute Carrier;
α-KG, α-ketoglutarate; MTS, mitochondria-targeting sequence; HRM, heme regulatory motif; IRP, iron
regulatory protein; ATP, adenosine triphosphate; ADP, adenosine diphosphate; AAA+, ATP hydrolase
associate with various cellular activities; ANT, adenine nucleotide translocator; KDH, α-ketoglutarate
dehydrogenase; CcO, cytochrome c oxidase; ETC, electron transport chain; SDH, succinate dehydrogenase;
CCHL, cytochrome c heme lyase; HCCS, holocytochrome c synthase; MLS, microphthalmia with linear skin
defects; TMD, transmembrane domain; FDX, ferredoxin; MAMs, mitochondria-associated membranes; ERMES,
endoplasmic reticulum-mitochondria encounter structure; MDV, mitochondrial-derived vesicle; HRG, heme
responsive gene; ZnMP, zinc mesoporphyrin; CHO, Chinese hamster ovary; LDL, low-density lipoprotein;
HDL, high-density lipoprotein; HO, heme oxygenase; FeLV, feline leukemia virus; ABC, ATP-binding cassette;
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BRCP, breast cancer resistance protein; HBP, heme-binding protein; FABP, fatty acid-binding protein; GAPDH,
glyceraldehyde phosphate dehydrogenase; PGRMC1/2, progesterone receptor membrane component 1/2;
EGFP, enhanced green fluorescent protein; ECFP, enhanced cyan fluorescent protein; EYFP, enhanced yellow
fluorescent protein HS, heme sensor; FRET, Forster resonance energy transfer.
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